Waiting times for radiotherapy: variation over time and between cancer networks in southeast England by Robinson, D et al.
Waiting times for radiotherapy: variation over time and between
cancer networks in southeast England
D Robinson*,1, T Massey
1, E Davies
1, RH Jack
1, A Sehgal
1 and H Møller
1
1Thames Cancer Registry, Division of Cancer Studies, Guy’s King’s and St Thomas’ School of Medicine, Capital House, 42 Weston Street, London SE1
3QD, UK
The aim of this study was to investigate variations in the length of time that patients with cancer wait from diagnosis to treatment with
radiotherapy. A total of 57426 men and 71018 women diagnosed with cancer between 1992 and 2001 and receiving radiotherapy
within 6 months of diagnosis were identified from the Thames Cancer Registry database. In total, 12 sites were identified for which a
substantial number or proportion of patients received radiotherapy: head and neck, oesophagus, colon, rectum, lung, nonmelanoma
skin cancer, breast, uterus, prostate, bladder, brain and non-Hodgkin’s lymphoma. Median waiting times from diagnosis to
radiotherapy were calculated, together with the proportion of patients who received radiotherapy within 60 days of diagnosis, and
analysed by year of diagnosis, cancer site, deprivation quintile, age at diagnosis, sex and cancer network of either residence or
treatment. Logistic regression was used to adjust the proportion receiving treatment within 60 days for the effects of the other
factors. There were significant differences in the proportions receiving radiotherapy within 60 days between different networks and
different cancer sites, which remained after adjustment. Median waiting times varied from 42 to 65 days across networks of residence,
with the adjusted proportion treated within 60 days ranging from 44 to 71%. There was no difference between male and female
patients after adjustment for the other factors, particularly site. There was a highly significant trend over time: the median wait
increased from 45 days in 1992 to 76 days in 2001, while the adjusted proportion being treated within 60 days declined by almost a
half, from 64 to 35%, over the same period.
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Over the past 5 years the UK government has introduced a series of
policies designed to decrease the time that patients wait from the
first suspicion of cancer to its investigation and definitive treatment.
In 1999 a policy proposed in 1997, stipulating a maximum 2-week
wait between urgent referral by a general practitioner and first
hospital appointment, was implemented for patients with suspected
breast cancer (Department of Health, 1997). This policy was
subsequently extended to include all cancer sites. Additional targets
relating to the investigation, diagnosis and treatment of cancer have
since been defined (Department of Health, 2000, 2004). In
particular, a target of a maximum 2-month wait from urgent GP
referral to treatment for all cancers has been set for 2005.
A number of UK studies have focused attention on waiting times
for cancer patients. A large retrospective survey of all English
patients diagnosed in October 1997 (Spurgeon et al, 2000) found
that the waiting time from initial referral to outpatient appoint-
ment and to treatment varied according to tumour type, whether
the initial referral was coded urgent, and by the region where
treatment was undertaken. For nonurgent referrals, patients with
breast cancer experienced the shortest waits (median wait of 14
days to first outpatient appointment and 35 days to first definitive
treatment) while patients with prostate cancer waited the longest
(median 41 days to first outpatient appointment and 111 days to
first definitive treatment). Patients with lung cancer experienced
intermediate waits (median 12 days to first outpatient appointment
and 47 days to first definitive treatment).
A number of smaller studies from single centres have also raised
concern. A study of 75 head and neck cancer patients in Liverpool
(Jones et al, 2002) reported a mean wait from GP to specialist
consultation of 5.1 weeks. The longest delay was the time taken to
the start of primary radiotherapy, which ranged from 4 to 18 weeks
(mean 10.3 weeks). Patients waited twice as long for radiotherapy
than for surgery as the definitive treatment. An audit of 29 lung
cancer patients awaiting radical radiotherapy in Glasgow
(O’Rourke and Edwards, 2000) found a median delay between
the first hospital visit and starting radiotherapy of 94 days. During
this time, six potentially curable patients became incurable.
The majority of studies investigating waiting times for cancer
patients have focused on whether longer waits affect survival. A
systematic review by Richards et al (1999) of 87 studies of breast
cancer found that patients with delays of 3 months or more from the
onset of symptoms to treatment had 12% lower survival than those
with shorter delays. However, longer delays were associated with
more advanced stage at time of treatment, and were not associated
with reduced survival once the effect of stage was taken into account.
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sA recent study by Mikeljevic et al (2004) found an increased
relative risk of death in breast cancer patients treated with
conservative surgery who subsequently waited longer than 9 weeks
for radiotherapy. Likewise, there is some evidence that a longer
wait for postoperative radiotherapy adversely affects survival for
patients with head and neck cancers, small-cell-lung cancer and
high-grade gliomas (Seel and Foroudi, 2002).
Conversely, a study of early glottic laryngeal carcinoma (Brouha
et al, 2000) found that the waiting time between diagnosis and
radiotherapy (median 43 days, range 9–180 days) had no effect on
the outcome. Similarly, the time to treatment did not affect
survival in patients with non-small-cell lung cancer in a UK study
(Bozcuk and Martin, 2001), or in those with pharyngeal cancer in a
study in Finland (Koivunen et al, 2001).
The interaction between delay and survival is complex. A study
of endometrial cancer in Scotland (Crawford et al, 2002) found
that women who experienced the longest delays to surgery were
more likely to survive, suggesting that general practitioners were
communicating information to consultants, enabling them to
respond faster to women at higher risk and decreasing their delay
between referral and first hospital visit. A similar interpretation
emerged from a study of breast cancer patients in Denmark
(Afzelius et al, 1994), where the prognosis was better for patients
with a long doctor’s delay compared with those with a short delay.
The authors concluded that doctors are effective at distinguishing
between more and less aggressive tumours.
A recent study of breast cancer patients in Germany (Arndt et al,
2003) found a U-shaped association between treatment delay and
stage at diagnosis, with the highest proportions of late-stage
tumours in women with either very short or very long delays, thus
suggesting that two different mechanisms are at work. Women
presenting with advanced disease may be diagnosed and treated
more quickly, because of the clearer clinical picture, while in those
presenting with very early symptoms diagnosis may be delayed by
false negative findings at the initial examination, resulting in
further advanced disease at the time of treatment.
Regardless of survival, any delay in the pathway from definitive
cancer diagnosis to treatment is likely to increase anxiety and
should be minimised if possible. In a previous study (Robinson
et al, 2003), in which we investigated the immediate effect of the
introduction of the government ‘2-week wait’ target, we found that
the wait from first hospital appointment to first treatment for
women with breast cancer in southeast England was
highly dependent on the type of treatment. The small group of
women who received radiotherapy as their first treatment
experienced long delays, with little more than half being
treated within the target time of 5 weeks from first hospital
appointment. The present study extends this analysis to cancers
other than breast cancer, and to a longer period of time. We have
examined the delay between the diagnosis of cancer at a number of
sites and the commencement of radiotherapy treatment, and the
variation in waiting times across cancer networks and over
calendar time.
SUBJECTS AND METHODS
The Thames Cancer Registry (TCR) covers a population of around
14 million people in London and the southeast of England. All
608952 registered cases of cancer that were diagnosed between
1992 and 2001 and resident within the TCR catchment area were
examined. Patients were regarded as having received radiotherapy
if a valid date of radiotherapy treatment within 6 months of
diagnosis was recorded. The date of diagnosis is defined as the date
on which cancer was confirmed by the best of the diagnostic tests
performed (ideally histological or cytological confirmation) or, if
not available, the date of admission to hospital for the malignancy
or, if not admitted, the date of first outpatient consultation. The
date of radiotherapy is the date on which active radiotherapy
treatment of any kind was begun.
Figure 1 shows how cases were selected for the study. In total,
133 patients, recorded as dying before they received either their
diagnosis or radiotherapy treatment, were excluded, together with
34 cases of male breast cancer in situ. Invasive male breast cancers
(575 cases) were retained. Overall, 131560 patients had received
radiotherapy. A small proportion (3116 cases, 2.4%) who were
recorded as receiving radiotherapy prior to their diagnosis were
subsequently excluded, and the analysis based on the 128444
patients who received radiotherapy after diagnosis.
In total, 12 cancer sites were identified for which a substantial
number or proportion of cases had received radiotherapy. These
were cancers of the head and neck, oesophagus, colon, rectum,
lung, female breast, uterus, prostate, bladder and brain, non-
melanoma skin cancer, and non-Hodgkin’s lymphoma. Female
Patients with RT Patients with RT
Patients with RT before diagnosis
131 560
608 785
All cases (year of diagnosis 1992 − 2001) 
608 952 (298 739m + 310 213f) 
Remaining patients
Patients excluded from analysis:
167 (65 with date of death < date of RT;
68 with date of death < date of diagnosis;
34 male breast in situ cases)
477 225
(RT = radiotherapy)
Patients included in analysis
128 444
(57 426m + 71 018f)
3116
(1513m + 1603f)
(58 939m + 72 621f) (239 697m + 237 528f)
Figure 1 Flow chart of patient selection.
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in situ cases, and brain tumours (which included tumours of the
meninges and of the pituitary and pineal glands) into malignant
and benign cancers. The ‘benign’ group also contained tumours of
‘uncertain or unknown behaviour’. Two thirds of the cases in this
group who received radiotherapy had pituitary tumours. The
‘bladder’ site included both invasive and in situ cases; all other
specified sites comprised only invasive cases. Finally, all remaining
cases were combined into an ‘other’ group. For the male patients,
this included the invasive breast cancer cases.
Age at diagnosis was calculated and grouped into five bands.
Cancer network of residence was determined from the postcode of
the patient’s address at the time of diagnosis, and network of
treatment from the hospital at which radiotherapy was provided.
Socioeconomic deprivation was assessed on the basis of postcode
of residence. Each subject was assigned to an appropriate ward,
and hence to a quintile of the ward income domain score, a
subcomponent of the indices of multiple deprivation (IMD) 2000
for England (Department of the Environment, Transport and the
Regions, 2000).
Logistic regression analysis was performed, with the dependent
variable being the receipt of radiotherapy within 60 days of
diagnosis. This provided a convenient cutoff close to the overall
median waiting time of 56 days, and corresponds to the 2-month
target for urgent referrals set for 2005 by the NHS Cancer Plan.
Factors included in the model were: year of diagnosis, site, IMD
quintile, age group, sex, and network of either residence or
treatment. Adjustment for length of survival after diagnosis was
achieved by including a dichotomous variable indicating whether
the subject had survived for less than 6 months or longer. This
simple adjustment gave similar results to an analysis that excluded
patients who died within 6 months of diagnosis, but enabled us to
retain more cases for analysis.
An alternative analysis was performed by fitting a Cox
proportional hazards model to the data. The results, which
are not presented here, were qualitatively the same as those
from the logistic model. We chose to present the latter as they are
easier to interpret. We present both the crude and adjusted
proportions receiving radiotherapy within 60 days, to give an
indication of the degree of sensitivity to case-mix adjustment. For
each factor, the proportions were adjusted to allow for differences
in all of the other factors, along with length of survival as detailed
above.
RESULTS
Table 1 shows the number of different cancers diagnosed during
the study period, together with the number and percentage of cases
receiving radiotherapy. There were a number of striking differ-
ences between the sexes: for head and neck cancer and for brain
tumours, the proportion of women receiving radiotherapy was
substantially lower than the corresponding proportion in men.
The results of the logistic regression analysis are shown in
Table 2. There was a highly significant variation in the proportion
of cases receiving radiotherapy within 60 days of diagnosis
between cancer network of residence. This remained after
adjustment for the other factors. The median wait for radiotherapy
varied from 42 to 65 days. When network of treatment was
included in the model instead of network of residence, the pattern
was almost identical (results not shown).
There was a highly significant trend in radiotherapy waiting
times over time. The median wait increased from 45 days in 1992
to 76 days in 2001, while the proportion being treated within 60
days declined from 64 to 40% over the same period. In the adjusted
model the gradient became even steeper, falling from 64 to 35%.
This is shown graphically in Figure 2.
There was significant variation between cancer sites: the longest
waits (and smallest percentages treated within 60 days) were seen
for cancers of the colon, breast, prostate and bladder, while the
shortest waits (and largest percentages treated within 60 days)
were found in brain and lung cancer cases. The differences
between different cancers were not sensitive to adjustment for the
other factors.
Figure 3 shows the unadjusted proportion of cases in each
cancer network of residence who received radiotherapy within 60
days, by different time periods. The first period (1992–1994)
represents the pre-Calman/Hine era, and the later period (1999–
2001) follows the introduction of government targets on waiting
times. Figure 4 shows a similar plot of unadjusted proportions by
cancer site. These graphs demonstrate the largely consistent
differences between cancer networks and between different types
of cancer, and the highly consistent downward trend over time.
Before adjustment for the other factors, there was a significant
trend in the proportion being treated within 60 days across the
IMD quintiles, with a greater proportion in the most deprived
group (quintile 5). This gradient disappeared completely after
adjustment for case-mix, and in the adjusted estimates there is a
Table 1 Numbers and percentages of cases receiving radiotherapy by sex and cancer site. All years combined (1992–2001)
Males Females
Cancer site Total cases No. (%) with radiotherapy Total cases No. (%) with radiotherapy
Head and neck 10617 6398 (60.3%) 6686 3290 (49.2%)
Oesophagus 8738 1872 (21.4%) 5699 1468 (25.8%)
Colon 20821 667 (3.2%) 23329 555 (2.4%)
Rectum 14229 3433 (24.1%) 11478 2398 (20.9%)
Lung 51621 17103 (33.1%) 30534 9286 (30.4%)
Nonmelanoma skin cancer 10834 1676 (15.5%) 6884 954 (13.9%)
Breast — — 89164 34162 (38.3%)
Breast in situ — — 5955 1192 (20.0%)
Uterus — — 17181 7051 (41.0%)
Prostate 55047 9211 (16.7%) — —
Bladder 22757 3453 (15.2%) 8788 1367 (15.6%)
Brain 5498 2363 (43.0%) 4374 1582 (36.2%)
Brain, benign 2720 316 (11.6%) 3725 232 (6.2%)
Non-Hodgkin’s lymphoma 10618 1595 (15.0%) 9338 1477 (15.8%)
Other 83623 9339 (11.2%) 85411 6004 (7.0%)
Total 297123 57426 (19.3%) 308546 71018 (23.0%)
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sTable 2 Median waiting times, and crude and adjusted proportions of patients treated with radiotherapy (RT) within 60 days from date of diagnosis, by
various factors
Total cases
No. (%) of cases
receiving RT Median wait (days)
Propn. treated within
60 days (%)
Adjusted
a propn. treated
within 60 days (%)
Cancer network of residence
A
b 12611 1442 (11.4%) 42 67.3 70.6
B 72783 16775 (23.0%) 62 49.1 46.4
C
b 28771 5547 (19.3%) 52 56.9 58.8
D
b 42015 10001 (23.8%) 63 48.1 46.8
E 58188 11707 (20.1%) 50 58.1 54.9
F 45889 9947 (21.7%) 54 55.0 53.4
G 59750 12094 (20.2%) 61 49.9 47.1
H 33032 7327 (22.2%) 49 61.3 61.4
I
c 54469 10809 (19.8%) 56 53.7 53.7
J 58050 13231 (22.8%) 54 56.0 55.0
K 60907 11003 (18.1%) 65 45.7 43.7
L
b 14386 2652 (18.4%) 62 48.9 45.7
M 64226 15818 (24.6%) 52 55.8 55.4
Other/not known 592 91 (15.4%) 49 64.8 58.9
Test for heterogeneity w
2¼1079.7 (Po0.001) w
2¼1263.6 (Po0.001)
Year of diagnosis
1992
c 59518 12181 (20.5%) 45 63.6 63.6
1993 56926 11654 (20.5%) 48 62.0 61.1
1994 59066 12855 (21.8%) 49 59.8 58.9
1995 59746 12982 (21.7%) 53 56.5 55.8
1996 62526 13787 (22.0%) 55 55.3 53.9
1997 62912 14411 (22.9%) 56 53.9 52.0
1998 61827 13717 (22.2%) 58 51.7 48.9
1999 61773 13221 (21.4%) 64 46.5 43.4
2000 62241 12297 (19.8%) 70 43.0 38.9
2001 59134 11339 (19.2%) 76 39.6 35.4
Test for trend w
2¼2675.6 (Po0.001) w
2¼3107.9 (Po0.001)
Cancer site
Head and neck 17303 9688 (56.0%) 54 57.4 56.3
Oesophagus 14437 3340 (23.1%) 46 63.8 53.0
Colon 44150 1222 (2.8%) 70 42.5 36.1
Rectum
c 25707 5831 (22.7%) 54 56.5 56.5
Lung 82155 26389 (32.1%) 35 73.1 61.9
Nonmelanoma skin
cancer
17718 2630 (14.8%) 48 63.1 57.2
Breast 89164 34162 (38.3%) 71 38.3 38.9
Breast in situ 5955 1192 (20.0%) 74 35.0 37.7
Uterus 17181 7051 (41.0%) 68 42.3 40.9
Prostate 55047 9211 (16.7%) 95 31.0 29.5
Bladder 31545 4820 (15.3%) 69 42.2 32.2
Brain 9872 3945 (40.0%) 35 82.9 82.0
Brain, benign 6445 548 (8.5%) 56 53.7 55.0
Non-Hodgkin’s
lymphoma
19956 3072 (15.4%) 64 46.7 42.0
Other 169034 15343 (9.1%) 45 62.3 56.1
Test for heterogeneity w
2¼11381.8 (Po0.001) w
2¼5899.7 (Po0.001)
IMD quintile
1
c 112942 25112 (22.2%) 58 52.0 52.0
2 119629 25400 (21.2%) 58 51.9 50.5
3 120101 25681 (21.4%) 57 52.7 50.5
4 128505 26811 (20.9%) 55 53.9 50.3
5 123740 25350 (20.5%) 54 55.6 50.7
Not known 752 90 (12.0%) 50 63.3 65.6
Test for trend w
2¼85.3 (Po0.001) w
2¼4.78 (P¼0.03)
Age at diagnosis
o50
c 70609 20341 (28.8%) 63 47.6 47.6
50–59 79565 24294 (30.5%) 62 48.8 50.4
60–69 132666 34725 (26.2%) 58 51.5 50.3
70–79 180470 35024 (19.4%) 52 56.4 53.1
80+ 142359 14060 (9.9%) 43 65.4 60.6
Test for trend w
2¼1258.8 (Po0.001) w
2¼349.9 (Po0.001)
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stendency for slightly shorter waiting times in the most prosperous
group.
There was also a significant trend related to age, with a greater
proportion of the older cases being treated within 60 days. This
trend was attenuated, but remained statistically significant, after
adjustment for the other factors.
Before adjustment, there was a highly significant difference
between the sexes, with 58% of men and 49% of women receiving
radiotherapy within 60 days. However, after adjustment for the
other factors this difference disappeared completely.
DISCUSSION
The main findings of this study are the differences in waiting
times for radiotherapy between different cancer networks
and different cancer sites, and the large increase in waiting
times observed over the 10-year period of the study.
Even after adjustment for other factors, large variation
remained between different cancer networks, with the proportion
receiving radiotherapy within 60 days of diagnosis ranging from
44 to 71%.
Table 2 (Continued)
Total cases
No. (%) of cases
receiving RT Median wait (days)
Propn. treated within
60 days (%)
Adjusted
a propn. treated
within 60 days (%)
Sex
Male
c 297123 57426 (19.3%) 50 58.4 58.4
Female 308546 71018 (23.0%) 62 49.1 58.4
Test for heterogeneity w
2¼1097.6 (Po0.001) w
2¼0.0 (P¼0.95)
All cases 605669 128444 (21.2%) 56 53.2
aAdjusted for all other factors, and for survival.
bTCR covers only a part of this network.
cReference group. Tests for heterogeneity and trend exclude ‘other’ and ‘not known’
categories.
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Figure 2 Proportion of patients receiving radiotherapy within 60 days, by year of diagnosis.
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Figure 3 Unadjusted proportion of patients receiving radiotherapy within 60 days, by cancer network of residence and period of diagnosis.
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sThe difference in the proportion receiving radiotherapy within
60 days between male and female patients was completely negated
after adjustment for the other factors, particularly site. A large
proportion of women with breast cancer (38%) or uterine cancer
(41%) received radiotherapy – sites for which the waiting time was
relatively high. Conversely, a smaller proportion of women than
men received radiotherapy for head and neck and brain cancers,
for which waiting times were shorter.
In the context of large variation in radiotherapy waiting times
between different cancers, it was not surprising to find variation
between socioeconomic groups, simply because the incidence of
different cancers varies between such groups. The tendency, after
case-mix adjustment, towards a slightly shorter waiting time in the
most prosperous group may be due to preferential treatment of
this group, but the difference is not large (52 vs 50–51% treated
within 60 days) and only marginally statistically significant,
despite the very large number of cases.
Although these findings may appear dramatic, our study has a
number of shortcomings. Our measure of waiting time (from
diagnosis to radiotherapy) is a crude one, containing a number of
intervals where delay is possible. There is a wait after diagnosis for
referral for radiotherapy, followed by a planning stage, and then a
further wait for treatment. From the point of view of the
radiotherapy department, a more relevant waiting time to analyse
would be from referral for radiotherapy to treatment, but our data
set did not have the dates required to calculate this. In any case,
what is most important to the individual patient is the total waiting
time for treatment.
We have not allowed for the effect on waiting times of
concomitant therapy such as surgery or chemotherapy. Again,
this was because we wanted to explore the broader picture.
However, repeating the analysis using a ‘truncated’ waiting time,
defined as the wait to radiotherapy from the immediately
preceding treatment in those patients who received some other
form of therapy between diagnosis and radiotherapy, or as the wait
from diagnosis to radiotherapy for those patients with no
intermediate treatment, produced qualitatively similar results.
Figure 5 shows the trends over time in the median values of these
two waits, along with the median wait from diagnosis to
radiotherapy in the smaller group of patients for whom radio-
therapy was the first treatment. Although the ‘truncated’ wait and
the wait from diagnosis in those receiving radiotherapy as their
first treatment are shorter, the patterns are similar for the three
measures.
There is also a possibility that radiotherapy treatment has been
under-ascertained in our data set (i.e. radiotherapy details are not
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Figure 4 Unadjusted proportion of patients receiving radiotherapy within 60 days, by cancer site and period of diagnosis.
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Figure 5 Median waiting times by year of diagnosis.
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srecorded), although this would be unlikely to be related in any
systematic way to the factors we have investigated.
A recent Canadian study (Johnston et al, 2004) of waiting times
from diagnosis to radiotherapy in patients with breast, lung,
colorectal or prostate cancer found differences in median waiting
times between the different cancer sites similar to those seen in our
study. Some of the observed differences between cancer sites can
be explained by the nature of the tumours concerned or the
associated radiotherapy. For example, head and neck cancers tend
to proliferate quickly and hence rapid treatment is required.
Likewise, radiotherapy for lung cancer is often largely palliative
and hence treatment can be delivered quickly and may involve
only a few fractions of radiation. The observed differences between
males and females in the proportions receiving radiotherapy for
certain types of cancer (Table 1) may be due to the varying
frequency of different subtypes of cancer between men and
women.
We found that older patients had shorter waiting times for
radiotherapy. Older people tend to receive a less radical treatment
regime (e.g. no concomitant chemotherapy) and hence are likely to
proceed to radiotherapy earlier. In the Canadian study (Johnston
et al, 2004), waiting times decreased with age for breast and
prostate cancer, but not for colorectal or lung cancer.
Our finding of increasing waiting times over the period of the
study is consistent with previous reports. Mikeljevic et al (2004)
found that the mean interval between conservative breast surgery
and radiotherapy increased from 5 to 12 weeks over a 10-year
period from the late 1980s to the late 1990s. Factors likely to
contribute to this effect include availability of trained staff and
equipment and increases in workload due to either an increased
incidence of cancer or changes in the management of tumours over
time, with larger numbers being referred for radiotherapy. The
latter would appear to be ruled out in our study: Table 2 shows that
the total numbers of registered cancers and also the numbers and
proportions of patients referred for radiotherapy have been
relatively stable over the study period. However, only radiotherapy
within 6 months of diagnosis was recorded on our database. It is
possible that there may be an increased number of cases receiving
radiotherapy more than 6 months after diagnosis in the more
recent years. If this is so, and if these had been included in our
analysis, then the observed trends over time would be even more
dramatic.
Another factor contributing to the lengthening waiting times
could be the increase in treatment complexity associated with the
recent widespread applications of 3-D conformal and intensity-
modulated radiotherapy. We were not able to explore the possible
effect on waiting times of changes in the number of patients
receiving palliative radiotherapy on recurrence.
The trend of increasing waiting times appears to have
accelerated since 1999 (see Table 2 and Figure 4), when the
government targets on waiting times from GP referral to first
hospital appointment were introduced. In an earlier study
(Robinson et al, 2003), we showed that this had a knockon effect,
with decreased waiting times during this earlier part of the cancer
pathway being offset by increased waits from first hospital
appointment to treatment – particularly for radiotherapy.
Although our data only permit analysis up to 2001, a recent
report from the Royal College of Radiologists (2003) found that the
proportion of patients waiting longer than 4 weeks to start radical
radiotherapy had increased from 28% in 1998 to 81% in 2002. They
concluded that ‘waiting lists are longer than ever’, that ‘modern
treatment is inhibited widely by lack of up to date equipment’, and
that ‘many departments cannot function at their full capacity
because they do not have the staff to allow them to do so’.
Likewise, a national audit of 2498 patients seen during 1 week in
2003 at all 55 radiotherapy centres in the UK (Ash et al, 2004)
found that median waiting times had increased by 2 weeks since
1998 for both radical and adjuvant radiotherapy, and that fewer
patients were being treated within the standards for good practice
set by the Joint Collegiate Council for Oncology (JCCO). The
percentage of patients waiting longer than the maximum times
advised by the JCCO had increased from 32% in 1998 to 72% in
2003 for radical treatments, from 25 to 60% for palliative
treatments, and from 39 to 62% for adjuvant treatments.
Waiting time is only a single aspect of care, and the overall
quality of care should be assessed with consideration of other
dimensions as well. Lilford et al (2004) have argued vigorously
against the use of comparative outcome measures (such as league
tables and star ratings) in a health care setting. Short waits are not
necessarily equivalent to best clinical practice. We are currently
analysing waiting times for a number of specific cancer sites
separately and in greater detail, taking into account the effects of
additional treatment and the extent of disease at diagnosis, and
also investigating the effects of longer waits on survival.
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